Flavahan, William A.
Drier, Yotam
Johnstone, Sarah E.
Hemming, Matthew L.
Tarjan, Daniel R.
Hegazi, Esmat
Shareef, Sarah J.
Javed, Nauman M.
Raut, Chandrajit P.
Eschle, Benjamin K.
Gokhale, Prafulla C.
Hornick, Jason L.
Sicinska, Ewa T.
Demetri, George D.
Bernstein, Bradley E.
Article History
Received: 3 December 2017
Accepted: 10 September 2019
First Online: 16 October 2019
Competing interests
: B.E.B. is an advisor and equity holder for Fulcrum Therapeutics, 1CellBio, HiFiBio and Arsenal Biosciences, is an advisor for Cell Signaling Technologies, and has equity in Nohla Therapeutics. G.D.D. reports relationships with Novartis, Bayer, Pfizer, EMD-Serono, Sanofi, Ignyta, Roche, Loxo Oncology, AbbVie, Mirati Therapeutics, Epizyme, Daiichi-Sankyo, WIRB Copernicus Group, ZioPharm, Polaris Pharmaceuticals, M.J. Hennessey / OncLive, Adaptimmune, GlaxoSmithKline, Blueprint Medicines, Merrimack Pharmaceuticals, G1 Therapeutics, CARIS Life Sciences, Bessor Pharmaceuticals, ERASCA Pharmaceuticals, CHAMPIONS Oncology, Janssen, PharmaMar; in addition, G.D.D. has a Use patent on imatinib for GIST, licensed to Novartis, with royalties paid to the Dana-Farber Cancer Institute.